Innovative RNA vaccines for tuberculosis targeting the mucosal immune system
RNA Vaccine Innovations for TB: Targeting the Mucosa
This study is working on a new RNA vaccine to help boost the immune system's fight against tuberculosis, especially in the lungs, and it's designed to be both effective and affordable for people who need it.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hdt Bio Corporation NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10813157 on NIH RePORTER |
What this research studies
This research focuses on developing a new type of RNA vaccine aimed at enhancing the immune response against tuberculosis (TB), particularly at mucosal sites such as the lungs. The approach involves using a novel RNA platform that has shown promise in previous vaccine developments, including COVID-19. By targeting specific protein antigens and utilizing advanced adjuvants, the goal is to create a more effective vaccine that can be produced cost-effectively. The research includes preclinical testing in animal models to evaluate the immune responses generated by the vaccine.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research would include individuals at high risk for tuberculosis infection, such as those living in endemic areas or with compromised immune systems.
Not a fit: Patients who are not at risk for tuberculosis or those who have already been vaccinated with existing TB vaccines may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective TB vaccine that significantly reduces the incidence of the disease.
How similar studies have performed: Other research has shown success with RNA vaccine platforms in generating strong immune responses, particularly in the context of COVID-19, suggesting potential for similar advancements in TB vaccination.
Where this research is happening
Seattle, United States
- Hdt Bio Corporation — Seattle, United States (Active)
Researchers
- Principal investigator: Reed, Steven Gregory — Hdt Bio Corporation
- Study coordinator: Reed, Steven Gregory
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.